Logo image of ORMP

ORAMED PHARMACEUTICALS INC (ORMP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ORMP - US68403P2039 - Common Stock

2.85 USD
0 (0%)
Last: 11/28/2025, 7:53:47 PM
2.9 USD
+0.05 (+1.75%)
After Hours: 11/28/2025, 7:53:47 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ORMP. ORMP was compared to 192 industry peers in the Pharmaceuticals industry. ORMP has a great financial health rating, but its profitability evaluates not so good. ORMP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ORMP had negative earnings in the past year.
ORMP had a negative operating cash flow in the past year.
In the past 5 years ORMP reported 4 times negative net income.
ORMP had a negative operating cash flow in each of the past 5 years.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -14.94%, ORMP is doing good in the industry, outperforming 62.50% of the companies in the same industry.
ORMP's Return On Equity of -15.64% is fine compared to the rest of the industry. ORMP outperforms 69.27% of its industry peers.
Industry RankSector Rank
ROA -14.94%
ROE -15.64%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

9

2. Health

2.1 Basic Checks

ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORMP has been reduced compared to 1 year ago.
ORMP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ORMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ORMP has an Altman-Z score of 8.76. This indicates that ORMP is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ORMP (8.76) is better than 82.81% of its industry peers.
ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.76
ROIC/WACCN/A
WACC8.29%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 26.81 indicates that ORMP has no problem at all paying its short term obligations.
ORMP's Current ratio of 26.81 is amongst the best of the industry. ORMP outperforms 94.27% of its industry peers.
ORMP has a Quick Ratio of 26.81. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
ORMP has a better Quick ratio (26.81) than 94.27% of its industry peers.
Industry RankSector Rank
Current Ratio 26.81
Quick Ratio 26.81
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ORMP have decreased strongly by -228.57% in the last year.
ORMP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ORMP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -30.19% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-92.67%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ORMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as ORMP's earnings are expected to decrease with -66.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORMP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (11/28/2025, 7:53:47 PM)

After market: 2.9 +0.05 (+1.75%)

2.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners17.77%
Inst Owner Change-0.22%
Ins Owners12.36%
Ins Owner Change2.67%
Market Cap116.85M
Revenue(TTM)N/A
Net Income(TTM)-24.16M
Analysts43.33
Price Target3.32 (16.49%)
Short Float %0.7%
Short Ratio1.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 58.43
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.05
BVpS3.77
TBVpS3.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.94%
ROE -15.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.08%
Cap/Sales 1.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.81
Quick Ratio 26.81
Altman-Z 8.76
F-Score3
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y-92.67%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.06%
OCF growth 3YN/A
OCF growth 5YN/A

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What is the fundamental rating for ORMP stock?

ChartMill assigns a fundamental rating of 3 / 10 to ORMP.


What is the valuation status of ORAMED PHARMACEUTICALS INC (ORMP) stock?

ChartMill assigns a valuation rating of 0 / 10 to ORAMED PHARMACEUTICALS INC (ORMP). This can be considered as Overvalued.


How profitable is ORAMED PHARMACEUTICALS INC (ORMP) stock?

ORAMED PHARMACEUTICALS INC (ORMP) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ORAMED PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ORAMED PHARMACEUTICALS INC (ORMP) is expected to decline by -92.67% in the next year.